Answers are grounded in this paper and cite their sources.
BACKGROUND: A phase 2 trial of high-dose IV ascorbate suggested reduced mortality in patients with ARDS, although trials in sepsis have failed to show clinical benefit. RESEARCH QUESTION: Does IV high-dose ascorbate improve outcomes in patients with sepsis at risk of or with ARDS? STUDY DESIGN AND METHODS: In this phase 2b multicenter randomized placebo-controlled trial, patients with known or suspected infection and either shock or acute hypoxemic respiratory failure were randomized to ascorbate (50 mg/kg IV every 6 hours for 5 days) or a matching placebo. The primary outcome was days alive and free of respiratory, renal, and circulatory organ support to day 28. Secondary outcomes included clinical and biological end points. INTERPRETATION: Ascorbate did not improve days free of organ failure, although no safety concerns were identified in this small study. Ascorbate was shown to reduce a biological marker of inflammation associated with adverse outcomes in sepsis and lung injury.
No takes yet. Share an insight, caveat, or question.
Files et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: